Recent advances on blinatumomab for acute lymphoblastic leukemia
Blinatumomab has been approved for patients with R/R B‑ALL and MRD+ B‑ALL
Although complete remission rate of B cell acute lymphoblastic leukemia (B‑ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody‑drug conjugates and chimeric antigen receptor T cell therapy are changing the therapy landscape for B‑ALL. Blinatumomab, a bi‑specific T cell engager, has been approved for patients with relapsed/refractory and minimal residual disease positive B‑ALL. This review summarized data from recent clinical trials of blinatumomab for B‑ALL treatment.
Improving response rates and overall survival in relapsed or minimal residual disease‑positive acute lymphoblastic leukemia addresses a critical unmet need for patients with limited treatment options and high mortality.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Acute Myeloid Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
- NCT05800210: Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
- Advancing the Diagnosis of Non‑Hodgkin Lymphoma Through Next‑Generation Sequencing in Developing Countries: An Evaluation of Progress — A Narrative Review
- The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia
- Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)